Merck Zocor has 59% market share at Henry Ford through market share discounts.
Executive Summary
ZOCOR HAS 59% HMG-CoA SHARE AT HENRY FORD HEALTH SYSTEM after the Merck and the health plan negotiated a preferred contract for the cholesterol-lowering agent, Henry Ford Hospital pharmacist Tony Petita reported at the Association for Pharmacoeconomics & Outcomes Research first annual meeting May 13 in Philadelphia. Merck's Zocor (simvastatin) was selected as Henry Ford's preferred cholesterol-lowering agent in the summer of 1995. Zocor had a 5% market share at Henry Ford in June 1994, one year before the switch.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth